Abstract
As a consequence of mammographic breast screening programmes, ductal carcinoma in situ is diagnosed with increasing frequency. There are widely disparate philosophies concerning diagnosis, classification and treatment. This review discusses the management of DCIS in light of the new data from randomised trials.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have